Andreas Bockisch

Andreas Bockisch's AcademicInfluence.com Rankings

Andreas Bockisch

Philosophy

#8589

World Rank

#11999

Historical Rank

Logic

#5622

World Rank

#7034

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Andreas Bockisch's Degrees

Doctorate Medicine University of Duisburg-Essen

Why Is Andreas Bockisch Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas Bockisch's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2014) (1949)
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 (2009) (1255)
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. (2003) (550)
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. (2003) (547)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (2012) (507)
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. (2004) (460)
Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival (2010) (393)
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. (2004) (345)
False-Positive FDG PET Uptake−the Role of PET/CT (2006) (298)
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors (2011) (262)
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. (2004) (258)
Combined PET/MRI: a new dimension in whole-body oncology imaging? (2009) (255)
Acquisition protocol considerations for combined PET/CT imaging. (2004) (250)
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. (2002) (236)
Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease (2009) (217)
Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy (2006) (216)
Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis (2012) (215)
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. (2002) (211)
Segmentation of PET volumes by iterative image thresholding. (2007) (201)
PET/CT for the staging and follow-up of patients with malignancies. (2009) (196)
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. (2008) (191)
The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors (2010) (188)
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status (2015) (180)
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. (2005) (168)
Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. (2009) (158)
German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease (2011) (158)
Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. (2005) (156)
Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma (2012) (153)
Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. (1996) (147)
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging (2010) (144)
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. (2004) (137)
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. (2018) (137)
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients (2009) (135)
Hybrid PET/MR imaging of the heart: feasibility and initial results. (2013) (129)
Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer (2008) (127)
Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. (2002) (122)
Detection of inflammation in patients with acute aortic syndrome: comparison of FDG-PET/CT imaging and serological markers of inflammation (2007) (121)
Health-related Quality of Life, Depression and Anxiety in Thyroid Cancer Patients (2006) (120)
Imaging of Brain Tumors with L-3-[123I]Iodo-α-Methyl Tyrosine and SPECT (1989) (120)
Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results (2005) (119)
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. (2006) (115)
Peripheral Osteopenia in Adult Patients with Insulin‐dependent Diabetes Mellitus (1995) (114)
Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer (2004) (109)
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data (2008) (109)
Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma (2012) (108)
SPECT/CT with 99mTc-MAA in Radioembolization with 90Y Microspheres in Patients with Hepatocellular Cancer (2009) (105)
68Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax (2011) (105)
Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography (2008) (105)
Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. (2005) (104)
Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. (2005) (96)
124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact (2007) (96)
Optimized dose planning of radioiodine therapy of benign thyroidal diseases. (1993) (96)
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? (2015) (93)
Simultaneous 68Ga-DOTATOC PET/MRI in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Initial Results (2013) (90)
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. (2013) (89)
Liver transplantation for patients with metastatic endocrine tumors: Single‐center experience with 15 patients (2006) (88)
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer (2018) (87)
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems (2008) (87)
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. (2006) (85)
Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. (2000) (85)
Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI. (2013) (84)
Dual Modality of 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Patients with Cervical Carcinoma of Unknown Primary (2005) (81)
The effect of MR surface coils on PET quantification in whole-body PET/MR: results from a pseudo-PET/MR phantom study. (2011) (80)
Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. (2005) (80)
Staging and follow-up of gastrointestinal tumors with PET/CT (2005) (79)
Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients (2012) (77)
Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. (2008) (77)
Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. (2007) (75)
Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using 124I PET Imaging (2014) (75)
TNM staging with FDG-PET/CT in patients with primary head and neck cancer (2007) (75)
Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer (2005) (74)
Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma (1997) (74)
Cancer of unknown primary. (2008) (73)
Whole-body 18F-FDG PET/CT in the presence of truncation artifacts. (2006) (72)
Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. (1995) (71)
Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. (2014) (71)
18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy (2012) (71)
Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET (2008) (67)
Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma (2009) (67)
FDG-PET/CT in oncology (2007) (66)
Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. (2001) (66)
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging (2010) (66)
Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. (2005) (66)
Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer (2011) (64)
Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows (2005) (64)
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons (2010) (63)
FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. (2007) (62)
Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results (2013) (62)
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer (2011) (59)
The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. (2000) (58)
Correlation of PET/CT Findings and Histopathology after Neoadjuvant Therapy in Non-Small Cell Lung Cancer (2008) (58)
Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT (2013) (56)
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. (2014) (55)
The value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with medullary thyroid cancer (2000) (55)
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT (2017) (53)
Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer (2010) (52)
"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? (2011) (52)
Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. (2003) (52)
Blood flow in the carotid arteries: quantification by using phase-sensitive MR imaging. (1989) (51)
Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT (2017) (49)
Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT (2005) (49)
Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer (2006) (49)
Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. (2003) (48)
Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study. (2001) (48)
Technetium-99m-HMPAO brain SPECT in medically intractable temporal lobe epilepsy: a postoperative evaluation. (1991) (48)
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer (2007) (47)
Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography (2007) (47)
Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging (2007) (47)
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. (2008) (46)
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET (2008) (46)
Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results (2013) (45)
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. (2012) (44)
124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer (2016) (44)
Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma (2013) (43)
Comparison of the Diagnostic Value of FDG-PET/CT and Axillary Ultrasound for the Detection of Lymph Node Metastases in Breast Cancer Patients (2012) (43)
Morphologic and Functional Changes in Nontumorous Liver Tissue After Radiofrequency Ablation in an In Vivo Model: Comparison of 18F-FDG PET/CT, MRI, Ultrasound, and CT (2007) (43)
Whole-body potassium and bone mineral density up to 30 years after urinary diversion. (1998) (42)
Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability (2017) (42)
Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT. (2016) (42)
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation : Initial results (2008) (42)
The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty. (2007) (40)
Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. (2011) (39)
Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. (2003) (39)
Integrated FDG PET/MR Imaging for the Assessment of Myocardial Salvage in Reperfused Acute Myocardial Infarction. (2015) (38)
Indium-111-pentetreotide in Graves' disease. (1998) (38)
Euthyroid goiter with and without nodules--diagnosis and treatment. (2012) (38)
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I (2015) (37)
High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases (2016) (37)
Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. (2004) (36)
Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck (2011) (36)
Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. (2012) (36)
Reorientation effect measurements of even mercury isotopes (1979) (36)
Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model (2017) (35)
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial) (2014) (34)
Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. (1989) (34)
Primary melanoma of urinary bladder. (1992) (33)
Positron emission tomography analysis of [1-(11)C] acetate kinetics in short-term hibernating myocardium. (1998) (32)
Selective Internal Radiotherapy (SIRT) of Hepatic Tumors: How to Deal with the Cystic Artery (2013) (32)
Diagnosis of a cardiac angiosarcoma by fluorine-18 fluordeoxyglucose positron emission tomography (2002) (32)
Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. (2004) (32)
HMPAO-SPECT imaging resembling Alzheimer-type dementia in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS). (1990) (31)
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. (2016) (31)
Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours (2015) (31)
[Update of the S2k guidelines : Surgical treatment of benign thyroid diseases]. (2018) (29)
[A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas]. (1991) (29)
In Vivo Visualization of Prostate-Specific Membrane Antigen in Adenoid Cystic Carcinoma of the Salivary Gland. (2016) (29)
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. (2013) (28)
Coulomb excitation and lifetime measurements of the 21+ states in 76, 82, 84Kr (1982) (28)
Incidental head and neck 18F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? (2009) (28)
Whole-body PET/CT-mammography for staging breast cancer: initial results. (2008) (28)
Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging (2008) (28)
Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer (2016) (27)
Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology. (2006) (27)
Imaging with 124I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? (2016) (27)
Szintigraphisch mehranreichernde Schilddrüsenknoten gehen überwiegend mit normwertigem TSH einher (2011) (27)
Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report (2003) (26)
Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. (2011) (26)
Neural substrates of good and poor recovery after hemiplegic stroke: a serial pet study (2011) (26)
Lymph node staging with dual-modality PET/CT: Enhancing the diagnostic accuracy in oncology (2006) (26)
Combined PET Imaging and Diffusion-Weighted Imaging of Intermediate and High-Risk Primary Prostate Carcinomas with Simultaneous [18F] Choline PET/MRI (2014) (26)
PET versus PET/CT dual-modality imaging in evaluation of lung cancer. (2010) (25)
Effects of Rosiglitazone on Radioiodine Negative and Progressive Differentiated Thyroid Carcinoma as Assessed by 124I PET/CT Imaging (2012) (24)
Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development (2009) (24)
Diagnosis of bone and joint infection by leucocyte scintigraphy (1990) (23)
The XbaI G>T Polymorphism of the Glucose Transporter 1 Gene Modulates 18F-FDG Uptake and Tumor Aggressiveness in Breast Cancer (2010) (23)
Hybrid imaging of the bowel using PET/MR enterography: Feasibility and first results. (2016) (23)
Optimized 124 I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer (2008) (22)
Selective internal radiation therapy of hepatic tumours: is coiling of the gastroduodenal artery always beneficial? (2014) (22)
Reorientation effect and multiple coulomb excitation measurements of 134Ba (1977) (22)
68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin (2016) (22)
Positron emission tomography/computed tomography improves diagnostics of inflammatory arteritis (2005) (22)
Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf-Hals-Karzinomen (1999) (22)
Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT (1996) (21)
[Whole-body tumor staging: MRI or FDG-PET/CT?]. (2004) (21)
Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer. (2016) (21)
Reorientation effect measurements of 122Te and 130Te (1976) (21)
Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies (2012) (21)
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. (2010) (21)
Physiological 18F-FDG uptake by the spinal cord: is it a point of consideration for cancer patients? (2012) (21)
124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. (2007) (21)
Tc-99m Labeled Monoclonal Antibodies Against Granulocytes (BW 250/183) in the Detection of Appendicitis (1993) (20)
[Scintigraphically "hot" thyroid nodules mainly go hand in hand with a normal TSH]. (2011) (20)
[Protective factors for anxiety and depression in thyroid cancer patients]. (2007) (20)
Intraoperative radiation therapy in liver tissue in a pig model: monitoring with dual-modality PET/CT. (2004) (20)
Burn injury by nuclear magnetic resonance imaging. (2010) (19)
[Changes in the blood picture after radioiodine therapy of thyroid cancer]. (1994) (19)
Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging (2014) (19)
A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization (2013) (19)
18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma (2013) (19)
FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results (2012) (18)
[Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology]. (2009) (18)
Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy (2018) (18)
Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. (2015) (18)
Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. (2009) (18)
Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography (2008) (18)
Vergleich von 201T1 und 99mTc-MIBI in der Nachsorge des differenzierten Schilddrüsenkarzinoms (1991) (18)
Metabolic Imaging Allows Early Prediction of Response to Vandetanib (2011) (17)
Non-invasive characterization of cardiac microvascular disease by nuclear medicine using single-photon emission tomography (1999) (17)
Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours--a single-centre experience. (2008) (17)
Influence of PET/CT-introduction on PET scanning frequency and indications (2007) (16)
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]. (2015) (16)
Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. (2010) (16)
Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma. (1998) (16)
[Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference "PET in Oncology": results of the Bone and Soft Tissue Study Group]. (2001) (16)
Pioglitazone therapy in progressive differentiated thyroid carcinoma (2012) (16)
Prognostic value of 18F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation (2015) (16)
Klinische Wertigkeit der Positronenemissionstomographie (PET) in der Diagnostik der Knochen- und Weichteiltumore 3. Interdisziplinäre Konsensuskonferenz „PET in der Onkologie“. Ergebnisse der Arbeitsgruppe Knochen- und Weichteiltumore (2001) (15)
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor- exprimierender Tumore Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours (2015) (15)
Gynaecomastia in a patient with a hCG producing giant cell carcinoma of the lung. Case report. (2009) (15)
Initial [18F]FDG PET/CT in high-risk DTC patients (2016) (15)
Pathologie des Schilddrüsenkarzinoms (2004) (14)
[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects (1997) (14)
Matched pairs for radionuclide-based imaging and therapy (2011) (13)
Changing trends of incidence and prognosis of thyroid carcinoma (2019) (13)
UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 (2009) (13)
Diagnosis of hyperfunctional thyroid nodules: impact of US-elastography. (2014) (13)
PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. (2006) (13)
Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma (2017) (13)
Accuracy of combined PET/CT in image-guided interventions of liver lesions: an ex-vivo study. (2006) (13)
Impairment of lymphocyte function following yttrium-90 DOTATOC therapy (2015) (13)
Time Course of Tumor SUV in 18F-FDG PET of Breast Cancer: Presentation of a Simple Model Using a Single Reference Point for Time Corrections of Tumor SUVs (2011) (12)
Somatostatin receptor scintigraphy in advanced renal cell carcinoma (2008) (12)
[Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]. (2010) (12)
Integrated 68Ga-HBED-CC-PSMAPET/MRI in patients with suspected recurrent prostate cancer (2017) (12)
Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system? (2013) (12)
Oblate shapes of200, 202, 204Hg (1979) (12)
Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease (2016) (12)
A direct determination of the sign of the interference term in the Coulomb excitation of 102Ru (1976) (12)
Recurrent schwannoma: Diagnosis with PET/CT (2002) (12)
A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. (2001) (12)
[Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer]. (1999) (11)
[Somatostatin receptor PET/CT (SSTR-PET/CT)]. (2018) (11)
68 Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation (2011) (11)
[Leydig cell tumor as a cause of hirsutism in a postmenopausal woman]. (2007) (11)
Chloride absorption in patients with a continent ileocaecal reservoir (Mainz pouch I). (1997) (11)
Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection? (2011) (11)
Feinnadelbiopsie (FNB) der Schilddrüse (2012) (11)
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. (2019) (11)
Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer (2011) (11)
Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. (2013) (11)
A novel view on dosimetry-related radionuclide therapy: Presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma (2009) (11)
Sperm cell dynamics in the female rabbit genital tract after insemination monitored by radiolabeled spermatozoa. (1993) (11)
Klinische Bedeutung der Schilddrüsenzytologie (2015) (10)
Magnetic resonance (MR) imaging of prostatic tumours, a comparison with X-ray CT and transrectal sonography (TRS). (1988) (10)
18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease (2016) (10)
PET versus PET/CT dual-modality imaging in evaluation of lung cancer. (2007) (10)
[Building the future together]. (2012) (10)
Properties of excited states in 102Pd (1977) (10)
124I in PET imaging: impact on quantification, radiopharmaceutical development and distribution (2006) (10)
[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. (2018) (10)
The analysis of elastic and inelastic scattering of alpha particles using a folding potential (1981) (10)
Value of 18F‐FDG PET/MRI for the outcome of CT‐guided facet block therapy in cervical facet syndrome: initial results (2017) (10)
Selective internal radiation therapy of hepatic tumors: procedural implications of a patent hepatic falciform artery (2014) (10)
124I Positron Emission Tomographic Dosimetry and Positron Emission Tomography/Computed Tomography Imaging in Differentiated Thyroid Cancer (2005) (9)
Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries. (2011) (9)
Myocardial perfusion abnormalities in patients with active acromegaly. (2003) (9)
Lutetium-177-PSMA-Radioligandentherapie (2018) (9)
Reorientation effect measurements and multiple coulomb excitation in102Ru (1979) (9)
Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients (2015) (9)
Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts? (2015) (9)
Evil radioactivity (2006) (9)
Kontinuierliche Sensitivitätssteigerung in der Schilddrüsenkarzinom-Nachsorge im Verlauf dreier Thyreoglobulin-IMA-Generationen (2003) (9)
Diagnostik hyperfunktioneller Schilddrüsenknoten (2014) (8)
Highly iodinated intravenous contrast material for PET/CT - a feasibility study. (2008) (8)
SPECT imaging with [123I]-β-CIT in Parkinsonism: comparison of SPECT images obtained by a single-headed and a three-headed gamma camera (2001) (8)
Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results. (2010) (8)
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor- exprimierender Tumore: DGN-Leitlinie (S1) (2015) (8)
Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer (2017) (8)
[Scintigraphic use of 87Y during 90Y therapy of bone metastases]. (1992) (8)
[Continously increasing sensitivity in thyroid cancer aftercare in the course of three generations of thyroglobulin IMAs]. (2003) (8)
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor-exprimierender Tumore (2015) (8)
[The effect of different chemoembolization materials on CT-based attenuation correction in PET/CT]. (2007) (8)
Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR (2016) (8)
[Somatostatin receptor status in non-medullary thyroid carcinoma]. (1999) (8)
Vorbehalte der DGN zur Nutzenbewertung der PET durch das IQWiG (2010) (8)
Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them? (2009) (8)
A determination of the sign of P3 = M01+21+M21+22+M22+01+ for 194Pt (1979) (7)
Prädiktion der pharmakologischen Wirkung von Octreotid bei Akromegalie mittels 111In-Pentetreotid-Szintigraphie und Berechnung eines hypophysären Uptake-Index (1997) (7)
Technetium-99m mercaptoacetyltriglycine clearance: reference values for infants and children (1995) (7)
[Somatostatin receptor scintigraphy in endocrine orbitopathy]. (1994) (7)
[Differentiated thyroid cancer]. (2015) (7)
Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin (2012) (7)
Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma (2011) (7)
Selektive intraarterielle Radiotherapie (SIRT) maligner Lebertumoren (2017) (7)
Improving perceptions of the quality of service in nuclear medicine (2003) (7)
Niedrigste effektive Radioiodaktivität zur Ablation des Schilddrüsenrestes bei Patienten mit differenziertem Schilddrüsenkarzinom (2015) (7)
Androgenproduzierender Leydig-Zell-Tumor des Ovars als Ursache von Hirsutismus bei einer postmenopausalen Frau (2007) (7)
[99mTc-MIBI-scintigraphy before parathyroid surgery?]. (1999) (7)
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study (2022) (7)
Identification of the missing f52 state in 201Hg by Coulomb excitation (1980) (6)
Expression of the cAMP Binding Protein EPAC1 in Thyroid Tumors and Growth Regulation of Thyroid Cells and Thyroid Carcinoma Cells by EPAC Proteins (2014) (6)
Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. (2003) (6)
[Nuclear medicine diagnosis of Alzheimer type dementia]. (2008) (6)
Initiale [18F]FDG-PET/CT bei Hochrisikopatienten mit differenziertem Schilddrüsenkarzinom (2016) (6)
Untersuchungen zum Somatostatinrezeptor-Status bei nicht-medullären Schilddrüsenkarzinomen (1999) (6)
Wertigkeit der Bildgebung für die Lymphknotenmetastasierung beim Nierenzell-, Blasen-, Prostata- und Peniskarzinom sowie dem Hodentumor (2005) (6)
An approach towards problem-based learning in virtual space (2010) (6)
Szintigraphische Verwendung von 87 bei der 90Y-Therapie von Knochenmetastasen (1992) (6)
Einfluss der Einführung von PET/CT auf das PETUntersuchungsspektrum und die Untersuchungszahlen - Ergebnisse einer Multizenterstudie (2007) (6)
Grundlagen und klinischer Nutzen von PET-CT (2004) (6)
Increase in DNA single-strand break rejoining by continuous exposure of human mononuclear blood cells to radioiodine ((131)I) in vitro. (1997) (6)
[PET and diagnostic technology evaluation in a global clinical process. DGN's point of view]. (2010) (6)
Clinical Results of Immunoscintigraphy in a Variety of Malignant Tumors with Special Reference to Immunohistochemistry (1986) (6)
18F-fluoride PET/CT for bone scanning (2012) (6)
124I-PET/CT images of differentiated thyroid cancer patients (2012) (5)
Urologisches Kooperations- und Forschungsprojekt „Retroperitoneale Fibrose“ (RPF) (2007) (5)
E-Learning in der Nuklearmedizin Eine Erhebung an deutschen Universitäten (2010) (5)
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer (2016) (5)
Dual-label studies with [125I]-3(R)/[131I]-3(S)-BMIPP show similar metabolism in rat tissues. (1999) (5)
Reorientation effect measurements for even mercury isotopes (1978) (5)
Differenzierte Schilddrüsenkarzinome (2014) (5)
Aktualisierung der S2k-Leitlinie (2018) (5)
Vergleich von 99mTc-HMPAO-markierten Leukozyten und 99mTc-Nanokolloid bei Osteomyelitiden (1988) (5)
[Principles of PET/CT and clinical application]. (2004) (5)
Integrated Assessment of Cardiac PET/MRI: Co-Registered PET and MRI Polar Plots by Mutual MR-Based Segmentation of the Left Ventricular Myocardium (2017) (5)
[Scintigraphic detection of malignancies with radioactively labelled tumor antibodies. Clinical results based on immunohistochemical research]. (2008) (5)
[Combination PET/CT with 124I positron rays in metastatic follicular thyroid carcinoma]. (2002) (5)
Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving (2012) (5)
HMPAO-SPECT bei zerebralen Anfällen (1988) (5)
Influence of therapy with iodine-131 on thyroid tissue pattern in colour and power Doppler sonography. (2002) (5)
Success rate of repeated fine needle aspiration biopsy of clinically suspicious thyroid nodules (2012) (5)
[HMPAO-SPECT in cerebral seizures]. (1988) (5)
Radioiodtherapie beim differenzierten Schilddrüsenkarzinom (2012) (4)
Thyroglobulin as Specific Tumor Marker in Differentiated Thyroid Cancer (2005) (4)
Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT (2016) (4)
18F-Fluorid-PET/CT in der Skelettdiagnostik – Rolle der Schwächungskorrektur (2012) (4)
Surveillance of TSH-suppressive levothyroxine treatment in thyroid cancer patients: TRH testing versus basal TSH determination by a third generation assay. (2002) (4)
[Comparison of 99m Tc-HMPAO-labeled leukocytes and 99m Tc-nanocolloid in osteomyelitis]. (1988) (4)
[Relationship between thyroglobulin and reliability of thallium 201 scintigraphy in differentiated thyroid cancer]. (2000) (4)
Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial (2014) (4)
Diagnostic accuracy of 18 F – FDG PET / CT and MR imaging in patients with adenoid cystic carcinoma (2018) (4)
Optimierung der Schilddrüsen- Feinnadelpunktion (2011) (4)
Qualitative und quantitative kernspintomographische Befunde der fokal nodulären Hyperplasie der Leber (1990) (4)
Somatostatinrezeptor-PET/CT (2018) (4)
[Metastases of a medullary carcinoma of the thyroid (follicular variant). Diagnosis and therapy using radioiodine]. (2008) (4)
Chemotherapie beim Schilddrüsenkarzinom (2004) (4)
Radionuklidtherapie von Knochenmetastasen mittels Radium-223 (2016) (4)
HMPAO-SPECT unter Karotiskompression (Matas-Test) in der Diagnostik vor zervikalen Tumoreingriffen mit möglicher Karotisbeteiligung (1991) (4)
[Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index]. (1997) (4)
[Therapy of bone metastases with radium-223. German guidelines]. (2016) (4)
[Clinical importance of thyroid gland cytology]. (2015) (4)
Bedeutung der TSH-Rezeptor-Antikörper für die Diagnose des Morbus Basedow sowie die Prognoseabschätzung der Schilddrüsenüberfunktion und der endokrinen Orbitopathie (2009) (4)
[Comparison of stress echocardiography and radionuclide ventriculography in the diagnosis of cardiomyopathy in patients receiving chemotherapy for malignant diseases]. (2008) (4)
Koronare Herzkrankheit und Herzinfarkt (2006) (4)
Bedeutung der Ganzkörper-Skelettszintigraphie im Rahmen des Staging von Malignomen im HNO-Bereich* (1992) (4)
[Early and late HMPAO-SPECT during an epileptic seizure]. (1990) (4)
[111-indium DTPA octreotide scintigraphy in colorectal liver metastases]. (1997) (4)
[Radionuclides--reasons and and teaching]. (2009) (4)
Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging (2016) (3)
124I-PET/CT in metastatic follicular thyroid carcinoma (2002) (3)
["Retroperitoneal Fibrosis" (RPF) Urologic Cooperation and Research Project]. (2007) (3)
Virtual 3-D 18F-FDG PET/CT panendoscopy for assessment of the upper airways of head and neck cancer patients: a feasibility study (2012) (3)
[Incidence of lesions described by magnetic resonance imaging in the clarification of focal epilepsy of frontal and temporal origin]. (1997) (3)
Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History (2017) (3)
[Optimization of the fine needle aspiration biopsy (FNAB) of thyroid nodules- automatic aspirator versus manual technique]. (2011) (3)
Static and dynamic radionuclide imaging in the diagnosis of the acute scrotum. (1991) (3)
Bedeutung der Hodenszintigraphie für die Differentialdiagnose des akuten Skrotums (1989) (3)
Quantification by Using Phase-Sensitive MR Imaging (1989) (3)
Strategischer Wandel bei der Anwendung bildgebender Systeme in der Kinderurologie (2008) (3)
PET/CT: Clinical Considerations (2004) (3)
Ganzkörpertumorstaging: MRT oder FDG-PET/CT? (2004) (3)
[Shaping the future together]. (2012) (3)
Lesion concordance, image quality and artefacts in PET/CT (2010) (3)
99mTc–MAG3–Nierenfunktionsszintigraphie ohne und mit Captopril zur Diagnostik der renovaskulären Hypertonie (1993) (2)
Dosimetrie bei Radioiodtherapie benigner Schilddrüsenerkrankungen – Hintergrund und Durchführung (2008) (2)
Water-equivalent oral contrast agents in dual-modality PET/computed tomography scanning: does a little barium make the difference? (2009) (2)
PET/CT and PET using [18F]-FDG in a Patient with Soft Tissue Sarcoma (2004) (2)
Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer (2005) (2)
Economic image compression of output documentation of the most frequent examinations in nuclear medicine. (2007) (2)
Zielgerichtete Therapie für Patienten mit Schilddrüsenkarzinom (2011) (2)
[HMPAO-SPECT during carotid artery compression (Matas test) in the evaluation of cervical tumor surgery with potential carotid involvement]. (1991) (2)
Beziehung zwischen Thyreoglobulin und der Treffsicherheit der Thallium-201-Szintigraphie differenzierter Schilddrüsenkarzinome (2000) (2)
Whole-Body PET/CT Tumour Staging with Integrated PET/CT-Colonography: Technical Feasibility and First Experiences in Patients with Colorectal Cancer (2005) (2)
[Relevance of Ablation Therapies for HCC: "A Real Bridging" for Liver Transplantation?]. (2016) (2)
PET/CT - Stellenwert beim Schilddrüsenkarzinom (2004) (2)
Inzidenz kernspintomographisch erfaßbarer Läsionen bei der Abklärung fokaler Epilepsien frontalen und temporalen Ursprunges (1997) (2)
Relationship between Thyroglobulin and Tumor Detectabilily with Thallium-201 in Differentiated Thyroid Cancer (2000) (2)
The role of [F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty (2)
E-Learning in der Nuklearmedizin (2010) (2)
FDG-PET/CT bei Bronchialkarzinomen (2003) (2)
[Scintigraphic display of an ectopic parathyroid adenoma using 99mTc-MIBI--2 case reports]. (1994) (2)
Discrepant salivary gland response after radioiodine and MIBG therapies. (2017) (2)
Application of CT Contrast Agents in PET-CT Imaging (2011) (2)
Rasch progredientes Rezidiv der kolumnären Variante eines papillären Schilddrüsenkarzinoms unter endogener TSH-Stimulation (2003) (2)
Induction of DNA Single-Strand Breaks by 131I and 99mTc in Human Mononuclear Blood Cells In Vitro and Extrapolation to the In Vivo Situation (2000) (2)
[The significance of testicular scintigraphy for the differential diagnosis of the acute scrotum]. (1989) (2)
Parametric oesophageal multiple swallow scintigraphy for validation of dysphageal symptoms during external beam irradiation of mediastinal tumours (2001) (2)
Cancer: The effect of radioiodine therapy after total thyroidectomy (2013) (2)
[Inhalation scintigraphy of the lung using the new ultrafine aerosol Technegas]. (1989) (2)
Imaging of Metastases from a Thyroid Carcinoma Using In Pentetreotide (1995) (2)
FDG-PET/MRI fused data sets for the detection of liver metastases in patients undergoing systemic anticancer treatment (2012) (2)
Radioaktivität ist böse: Subjektive Konzepte von Radioaktivität bei Schilddrüsenpatienten vor einer möglichen Radioiodtherapie (2006) (2)
124I-PET/CT-Bildgebung bei Patienten mit Schilddrüsenkarzinomen – Unterscheidung zwischen Schilddrüsenrest und Lymphknotenmetastasen durch kinetische Größen (2012) (2)
Examination of the Somatostatin Receptor Status in Non-medullary Thyroid Cancer (1999) (2)
[Diagnostic evaluation of acute scrotum--testicular perfusion scintigraphy]. (1993) (2)
Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients: present and future applications (2012) (2)
The influence of the location of thyroid cancer metastases on tumor detectability with Thallium-201 (1997) (2)
Ist die Entwicklung des PET mit dem PET/CT beendet? (2005) (1)
[E-learning in nuclear medicine - a nationwide survey in Germany]. (2010) (1)
Stopping power for Ge ions produced by inelastic scattering of (d,t) fusion neutrons (1982) (1)
Dosimetric considerations for the radioembolisaton of hyperperfused liver tumors with Y-90 microspheres (2008) (1)
[Automatic setting of the contrast range of whole body scintigrams using a histogram method]. (1997) (1)
Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial (2021) (1)
[Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers]. (2005) (1)
Small scale dosimetry and modeling for salivary gland toxicity in thyroid cancer patients treated with 131I (2018) (1)
Abklärung des akuten Skrotums: Hodenperfusionsszintigraphie : Isotopenuntersuchung in der Urologie (1993) (1)
Automatische Läsionserkennung und Auswertung in der PET/CT: Evaluation einer neuen Software am Beispiel des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) (2009) (1)
Dosisplanung bei der Radiojodtherapie benigner Schilddrüsenerkrankungen (1992) (1)
Thyroid-specific Tumor Markers (2009) (1)
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters. (2009) (1)
[99mTc-MAG3-kidney function scintigraphy without and with captopril in the diagnosis of renovascular hypertension]. (1993) (1)
Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodules (2008) (1)
[Antihemolytic effect of various benzodiazepines on human erythrocytes]. (1976) (1)
Inhalationsszintigraphie der Lunge mit dem neuen ultrafeinen Aerosol »Technegas« (1989) (1)
[Importance of whole body skeletal scintigraphy within the scope of staging of neoplasms in the ENT area]. (1992) (1)
[Evaluation criteria for captopril-kidney function scintigraphy using 99mTc-MAG3]. (1993) (1)
Ga-68-DOTATOC-PET/CT imaging and somatostatin receptor- (sst-) fingerprints in apparently normal human tissues: SUVmax meets mRNA expression (2009) (1)
Value of Low Levels of Anti-TPO Antibodies in Patients With Suspicion of Hashimoto Thyroiditis (2007) (1)
Angiography-Based CArm CT for the Assessment of Extrahepatic Shunting before Radioembolization Stellenwert der Rotationsangiographie für die Detektion extrahepatischer Shunts vor Radioembolisation (2010) (1)
Gemeinsam die Zukunft gestalten (2012) (1)
Die Eignung des mittleren akustisch evozierten Potentials P35 für frequenzspezifische Messungen (1985) (1)
Assay-Abhängigkeit der Calcitonin- Zielbereiche für „biochemisch geheilte“ Patienten mit medullärem Schilddrüsenkarzinom (2012) (1)
Beurteilungskriterien für die Captopril-Nierenfunktions- szintigraphie mit 99mTc-MAG3 (1993) (1)
Towards MR-based attenuation correction for whole-body PET/MR imaging (2006) (1)
111-Indium-DTPA-Octreotid-Szintigraphie bei kolorektalen Lebermetastasen (2006) (1)
[Impact of nuclear medicine imaging techniques for lymph node surgery]. (2009) (1)
[Growth hormone: effect on bone metabolism and bone density]. (1996) (1)
Der Schilddrüsenknoten und der Stellenwert der Tumormarkerbestimmung (2008) (1)
first-line chemotherapy in advanced-stage Hodgkin lymphoma progression or early relapse for patients with residual disease after Positron emission tomography has a high negative predictive value for (2013) (1)
1 + 1 = 3. (2005) (1)
Die „Standard“-Schilddrüsenszintigrafie – ist sie noch zeitgemäß? (2020) (1)
Szintigraphische Darstellung ektoper Nebenschilddrüsen-adenome mit 99mTc-MIBI -2 Fallbeispiele (1994) (1)
Abstract46: Correlation of Residual SUV in Preoperative18F-FDG-PET/CT-Scans With Clinical and Histopathological Findings After Neoadjuvant Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (2006) (1)
Imaging cerebral blood flow with Technetium-99m HMPAO after head injury associated with consecutive transitional apallic syndrome (1992) (1)
Incidence of Lesions as Described by MRI in Focal Epilepsy of Frontal and Temporal Onset (1997) (1)
DNA lesions correlate with lymphocyte function after selective internal radiotherapy (2019) (1)
Problem-orientiertes Lernen im virtuellen Raum: Erste Erfahrungen in der Nuklearmedizin (2010) (1)
[Influence of the calcitonin assay on the definition of biochemical cure in patients with medullary thyroid carcinoma]. (2012) (1)
Konkordanz, Bildqualität und Artefakte im PET/CT (2010) (1)
Wasser-äquivalente orale Kontrastmittel im PET/CT: Macht eine kleine Menge Barium den Unterschied aus? (2007) (1)
Effektivität der PET/CT-assistierten Radiofrequenzablation maligner Lebertumoren – Ergebnisse im 2-Jahres-Follow-up (2008) (0)
Coronary calcium predicts presence and extent but not localization of exercise-induced myocardial perfusion defects (2002) (0)
Definition of retrosternal thyroid growth (2012) (0)
Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas -final results of the PETAL trial (2017) (0)
Predictors of Longer Survival after Radioembolization in Unilobar and Bilobar Advanced Hepatocellular Carcinoma with Yttrium-90 (2016) (0)
Where there is no PET/CT. (2008) (0)
Only trained staff defines indication. (2008) (0)
Der Schilddrüsenknoten und der Stellenwert der Tumormarkerbestimmung Thyroid Nodule and the Value of Tumormarkers (2008) (0)
The diagnostic significance of magnetic resonance imaging in prostatic tumours (2006) (0)
Ultrasound-guided fine-needle aspiration biopsy of clinically suspicious thyroid nodules with an automatic aspirator: a novel technique. (2012) (0)
Quantitative response assessment by interim FDG-PET in aggressive non-Hodgkin lymphoma (NHL) using SUV change and lymphoma-to-reference tissue ratios (2011) (0)
Differentiated Thyroid Cancer Using Assessment of Lesion Response in the Initial Radioiodine Treatment of (2014) (0)
PO-0670: Decrease in tumor SUVmax during definitive or neoadjuvant RT/CT is a prognostic factor in LAD lung cancer (2015) (0)
SUNDAY, SEPTEMBER 2ND 2012 57. Functional imaging in pulmonary oncology and COPD. Radiation dose in chest CT: survey and real life (2012) (0)
Distinguishing lymph node metastases from thyroid remnants in differentiated thyroid cancer patients using kinetic parameters estimated from I-124-PET/CT images (2012) (0)
Development and characterization of a triple-modality anti-PSMA targeting agent for immuno-SPECT/CT, near-infrared fluorescence imaging and targeted photodynamic therapy of PSMA-expressing tumors (2016) (0)
745 The Role of Selective Internal Radiotherapy with Yttrium-90 Glass Microspheres in Advanced Hepatocellular Carcinoma +/− Portal Vein Thrombosis – A European Pilot Phase II Study (2009) (0)
[Scintigraphic panoramic imaging of the jaws]. (1991) (0)
Inhalt, Vol. 12, Supplement 1, 1989 (1989) (0)
Tu1930 Simultaneous Positron Emission Tomography (PET) With 18F-Fluorodeoxyglucose (18F-FDG) With MRI Enterography for Monitoring Activity of Inflammation in Patients With Crohns Disease - A Pilot Study (2016) (0)
111In-pentetreotide scintigraphy in thyroid-associated orbitopathy. (2009) (0)
Clinical value of three-dimensional (3D) Image presentation in Single photon emission computed tomography (1995) (0)
Gastrointestinal 18F-FDG uptake in PET/CT without corresponding morphological mass: Early predictor of cancer development? (2009) (0)
Correspondence (letter to the editor): Inconsistencies (2014) (0)
P-7-11 Benzodiazeine receptor occupancy during lorazepam treatment in relation to plasma levels: A study with iomazenil-SPECT (1995) (0)
Thyroid Nodule and the Value of Tumormarkers (2008) (0)
C-Reactive Protein the Best Survival Predictor in 100 HCCs with Portal Vein Thrombosis after Radioembolization with Yttrium-90 (2016) (0)
Staging Solid Tumors with 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (2008) (0)
Indium-i 11-Pentetreotide Scintigraphy in Graves â€˜Ophthalmopathy (2006) (0)
The presence and extend of liver metastases are frequently understimated in patients with neuroendocrine tumor of small bowel (2016) (0)
PET/CT in der Onkologie (Antwortbogen) (2004) (0)
[Gallium scintigraphy in the diagnosis of osteomyelitis]. (1987) (0)
Imaging of PSMA expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT (2016) (0)
Contents Vol. 73, 2007 (2008) (0)
[Ectopic ureterocele--diagnosis and therapy]. (1988) (0)
[Qualitative and quantitative NMR tomographic findings in focal nodular hyperplasia of the liver]. (1990) (0)
Y-90 microsphere dosimetry in hepatic malignancies (2009) (0)
256 LONG TERM CLINICAL AND BIOCHEMICAL COMPARATIVE ANALYSIS AFTER SELECTIVE INTERNAL RADIOTHERAPY WITH YTTRIUM-90 MICROSPHERES IN HEPATOCELLULAR CARCINOMA (2013) (0)
Staging of progressive papillary, follicular, or medullary thyroid carcinomas: Comparison of various staging procedures to define the extent and progress of disease (2006) (0)
[The modification of 201Tl-SPECT of the myocardium by breast absorption]. (1989) (0)
[Suitability of the middle acoustic evoked potential P35 for frequency-specific measurements]. (1985) (0)
Diagnostic benefit of 131-Jod-SPECT/CT on patients after radioiodinetherapy of differentiated thyroid cancer (2009) (0)
Staging of non-small-cell lung cancer with FDG-PET/CT: Is there a correlation of morphologic tumor characteristics and metabolic activity? (2012) (0)
18F-fluoroethylcholine PET/MR imaging in salivary adenoid cystic carcinoma (2015) (0)
Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma (2017) (0)
Survival and response after selective internal radiation therapy (SIRT) for advanced hepatocellular carcinoma with and without portal vein thrombosis (2009) (0)
Automated detection and assessment of NSCLC using a novel PET/CT software tool: Initial results (2009) (0)
[Immunoscintigraphy with MAb B72.3 for preoperative detection of lymph node metastases of colorectal carcinoma]. (1995) (0)
Chemotherapy with doxorubicin in progressive medullary, follicular, and papillary thyroid carcinomas (2006) (0)
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status (2017) (0)
Direct determination of the sign of the multiple Coulomb excitation interference term in $sup 102$Ru (1975) (0)
MR-PET in Breast Cancer (2014) (0)
PET/CT in der Onkologie (CME-Fragebogen) (2004) (0)
Gastrointestinal tumors and PET/CT (2008) (0)
Whole-body FDG-PET/CT for re-staging patients with recurrent breast cancer (2006) (0)
Reply to: Appearances are often deceptive (2018) (0)
18. 99Tcm-MIBI scintigraphy in the detection of parathyroid adenomas: an evaluation of sensitivity and specificity (1994) (0)
Therapiemonitoring mit 18F-FDG-PET / CT (2008) (0)
Somatostatin Receptor Imaging In Recurrent Medullary Thyroid Cancer (2004) (0)
CT-based attenuation correction in lung perfusion SPECT-CT improves quantitative lesion contrast in patients with pulmonary embolism (2014) (0)
UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 . 0 (2018) (0)
Effects of dose inhomogeneities on normal tissue complication probability (NTCP) after Y-90 SIRT (2012) (0)
[A comparison of the value of magnetic resonance tomography and computed tomography in Nelson syndrome patients]. (1992) (0)
Quantitative Determination of Renal 99mTc-MAG3 Clearance. A Comparison of Results Acquired Simultaneously in Whole Body Geometry and with a Gamma Camera in ROI-Technique (1997) (0)
370 INTERNAL RADIOTHERAPY WITH 90YTTRIUM GLASS MICROSPHERES (THERASPHERE) FOR LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA: PROSPECTIVE VALIDATION OF SAFETY AND EFFICACY IN A EUROPEAN PILOT STUDY (2008) (0)
MR imaging in patients with adenoid cystic carcinoma (2020) (0)
[Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy]. (1995) (0)
Positron Emission Tomography guided therapy of aggressive lympomas (PETAL) - the predictive value of quantitative PET (2015) (0)
HMPAO-SPECT during Epileptic Seizures: Early and Late Images (1990) (0)
Post-radiosynovectomy imaging utilizing Erbium-169 citrate. (2019) (0)
51 RESPONSE RATE ACCORDING TO WHO, RECIST AND EASL CRITERIA AFTER RADIOEMBOLIZATION OF YTTRIUM-90 GLASS MICROSPHERES IN ADVANCED HEPATOCELLULAR CARCINOMA: A EUROPEAN PILOT PHASE II STUDY (2009) (0)
[Has the development of PET come to an end with PET-CT?]. (2005) (0)
Treatment options in progressive medullary, follicular, and papillary thyroid carcinomas: Evaluation of chemotherapy with doxorubicin (2006) (0)
PET Versus PET/CT Dual-Modality in Evaluation of Lung Cancer (2010) (0)
FDG-PET/CT for axillary lymph node staging extends the indication for sentinel lymph node biopsy in breast cancer patients (2009) (0)
Correlation of radionuclide ventriculography with roentgenological findings in chemotherapy patients. (2000) (0)
Repair of DNA single strand breaks can be stimulated by I-131 in human mononuclear blood cells in vitro (1995) (0)
The influence of the position, size, and shape of the thyroid nodule on the measured iodine-131 uptake value (1998) (0)
Iomazenil-SPECT imaging in Psychiatric diseases (1995) (0)
Stress echocardiography compared with radionuclide ventriculography in the diagnosis of cardiomyopathy in patients receiving chemotherapy for malignant tumour (1997) (0)
[Nuclear medicine]. (2009) (0)
Myelotoxicity in radioiodine therapy of differentiated thyroid carcinoma with regard to pretherapeutic blood dosimetry with iodine-124 (2009) (0)
Subject Index Vol. 73, 2007 (2008) (0)
Subjective perception of radioactivitypost successful treatment with radioiodine (2009) (0)
Dynamic [18F]2-FDG-PET-imaging in patients with GLUT1-deficiency syndrome before and on a ketogenic diet (2004) (0)
[Malignant pheochromocytoma of the urinary bladder. Case report and review of the literature]. (1993) (0)
[Rapid diagnosis of recurrence of a tall cell variant of papillary thyroid cancer by endogenous TSH stimulation]. (2003) (0)
Efficacy and safety of 124I-mIBG dosimetry-guided high activity 131I-mIBG therapy of advanced pheochromocytoma or neuroblastoma. (2023) (0)
9. Preliminary 99Tcm-MAG3 clearance 'normal' values in infants (1992) (0)
Ga-68-DOTATOC and F-18-FDG PET in progressive metastatic medullary thyroid cancer: Preliminary results (2008) (0)
PET/CT in der Onkologie (2004) (0)
Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability (2017) (0)
Cologne (2021) (0)
Comparison of Y-90 SIRT dosimetry strategies based on modeling normal tissue complication probability (NTCP) (2010) (0)
Radioimmunodetection (RID) with 131 I-labeled monoclonal anti-beta HCG-antibodies in testicular tumors. (1990) (0)
[Bone marrow scintigraphy and magnetic resonance tomography in plasmacytoma]. (1989) (0)
P1003 SELECTIVE INTERNAL RADIOTHERAPY WITH YTTRIUM-90 MICROSPHERES FOR HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN THROMBOSIS (2014) (0)
Case reports Burn injury by nuclear magnetic resonance imaging (2010) (0)
Standard “-Schilddrüsenszintigrafie – ist sie noch zeitgemäß ? Thyroid scintigraphy – is its clinical significance still justified ? (2020) (0)
Diagnostic Criteria in 99mTc-MAG3 Renal Function Scintigraphy with Captopril (1993) (0)
Whole-Body Imaging in Oncology: Positron Emission Tomography/Computed Tomography (PET/CT) (2008) (0)
Early psychopathological symptoms in senile dementia of the Alzheimer type (1989) (0)
Impressum, Vol. 12, Supplement 1, 1989 (1989) (0)
[Changes in the spine with MRI and skeletal scintigraphy after supra- and infradiaphragmatic radiotherapy of patients with Hodgkin's disease]. (1995) (0)
Attenuation of 201Tl-Chloride Myocardial SPECT Images by the Female Breast (1989) (0)
[Immunoscintigraphy and immunotherapy]. (1989) (0)
Introduction of an innovative follow-up concept for patients with differentiated thyroid carcinoma based on the dynamics of ultrasensitive measured thyroglobulin values (2015) (0)
Radionuclide Imaging with 99mTc-Sestamibi in Atypical Localised Parathyroid Adenomas (1994) (0)
PET-CT for Patients (pts) Selection within a Multimodality Treatment Protocol (CTx + CTx/RTx ± S) in Pts with Locally Advanced (LAD) Non-Small Cell Lung Cancer (NSCLC)(Inoperable Stage IIIA/Selected IIIB) (2005) (0)
Mesenchymale Tumoren des Gastrointestinaltrakts (2007) (0)
Radioembolisation von Lebertumoren: hepatopulmonale Shuntreduktion nach Sorafenib-Therapie (2012) (0)
Die „Erleuchtung“ der Drüsen: Nuklearmedizinische Diagnostik und Therapie endokriner Tumoren (2005) (0)
Vergleich der Wertigkeit von Magnetresonanztomographie und Computertomographie bei Patienten mit Nelson-Syndrom (1992) (0)
Zweizeitige Quantifizierung der Radionuklidspeicherung bei axillären Lymphknotenmetastasen des Mammakarzinoms in der FDG-PET/CT: Können physiologische Lymphknoten von Metastasen unterschieden werden? (2009) (0)
Vergleich von CT, PET/CT und MRI in der Verlaufskontrolle nach RF-Ablation colorektaler Lebermetastasen (2007) (0)
Vergleich von Ganzkörper-MRT und kombinierter PET/CT zum Staging bei der Erstdiagnose von Bronchialkarzinomen (2005) (0)
Hybridgerte Status quo und zuknftige Entwicklung PET/MR (2008) (0)
Positronen-Emissions-Tomography (PET) mit 18F-Fluorodeoxyglukose (18F-FDG) und simultaner MRT Enterografie in der Diagnostik von Morbus Crohn – eine Pilotstudie (2016) (0)
PET/MRT mit 68Ga-DOTATOC in der Diagnostik neuroendokriner Tumoren – Erste Resultate (2013) (0)
Simultane [18F] Cholin PET/MRT der Prostata: erste klinische Ergebnisse (2013) (0)
Poster zum Thema „Varia“ (CT, PET/SPECT/Szintigraphie) Tumorstaging in der Onkologie: Genauigkeit der Ganzkörper-FDG-PET/CT (2004) (0)
Metastasiertes (2020) (0)
Detektion von Schilddrüsenrestgewebe und Lymphknotenmetastasen mit Jod-124 beim differenzierten Schilddrüsenkarzinom (2010) (0)
Präoperative Bildgebung bei primärem Hyperparathyreoidismus (2007) (0)
Automatische Kontrasteinstellung von Ganzkörperszintigrammen mit einer Histogramm-Methode (1997) (0)
Genauigkeit der kombinierten PET/CT beim präoperativen Staging des nicht-kleinzelligen Bronchialkarzinomes (2004) (0)
Stellenwert einer sequentiellen Therapie mit Chemoembolisation, Thermoablation und selektiver interstiteller Radiatio bei Patienten mit fortgeschrittenem hepatozellulärem Karzinom (2009) (0)
Postinterventionelle Kontrolle des Ablationserfolges von malignen Lebertumoren: Vergleich von PET/CT und MRI (2006) (0)
Einfluss verschiedener Materialien zur Chemoembolisation auf die Schwächungskorrektur in der PET/CT, eine retrospektive Studie mit 19 Patienten (2006) (0)
Benzodiazepinrezeptordarstellung mit JOMAZENIL-SPECT (1993) (0)
Gewebeveränderungen in der Randzone der Nekrose nach Radiofrequenzablation der Leber: Darstellung mit unterschiedlichen bildgebenden Verfahren (2006) (0)
FusionJ: Ein Programmpaket für die nicht-lineare, nicht-affine Koregistrierung tomographischer Bilder (2009) (0)
Simultane (18F) FDG PET/MRT bei Patienten mit Kopf-Hals-Tumoren (2013) (0)
C-reaktives Protein ist ein Prädiktor des Gesamtüberlebens nach intraarterieller Radiotherapie hepatozellulärer Karzinome (2015) (0)
Prognostische Bedeutung der Expression des c-erbB 2- Onkoproteins beim papillären Schilddrüsenkarzinom (2005) (0)
Genauigkeit der kombinierten PET/CT zur Therapiekontrolle nach Radiofrequenzablation kolorektaler Lebermetastasen (2005) (0)
Vergleich der diagnostischen Genauigkeit der Ganzkörper- FDG-PET/CT und des konventionellen Algorithmus zum Staging des primären Mammakarzinoms (2012) (0)
Rezeptordarstellung mit der Single Photonen Emissions Computertomographie (SPECT): Stand der Forschung und Perspektiven (1996) (0)
Selektive intraarterielle Radiotherapie (SIRT) mit 90Yttrium-Mikrosphären bei intrahepatisch fortgeschrittenem hepatozellulärem Karzinom (2009) (0)
Subjektive Konzepte von Radioaktivität (2010) (0)
Postoperative FDG-PET/CT nach R0 Resektion eines gastrointestinalen Stromatumors: Gibt es einen klinischen Benefit bei Hoch-Risiko-Patienten (2007) (0)
124I-PET-Dosimetrie bei fortgeschrittenem differenzierten SchilddrÃ1⁄4senkarzinom: Therapeutische Relevanz (2017) (0)
Einseitige Radioembolisation der Leber mittels Yttrium-90 und ihre Auswirkungen auf Volumenveränderungen der Leberlappen (2012) (0)
Beeinflussung der 201TI-SPECT des Myokards durch die Mamma-Absorption (1989) (0)
Ganzkörper-PET/MRT mit 18F-FDG versus Ganzkörper-PET/CT in der Rezidivdiagnostik von gynäkologischen Tumoren des kleinen Beckens – erste Ergebnisse (2013) (0)
Benzodiazepinrezeptorbindung im [123I]-IOMAZENIL-SPECT in Relation zu Cortisol-Plasmaspiegeln (1996) (0)
„Standardized uptake values“ von [18F]-FDG in gesunden Organen: Vergleich zwischen Ganzkörper PET/CT und PET/MRT (2013) (0)
Radioembolisation mit 90Yttrium-Glas Microsphären (TheraSphere®) bei intrahepatisch fortgeschrittenem hepatozellulärem Karzinom (2008) (0)
Inzidentelle cervikale FDG-Anreicherung ohne korrespondierendes morphologisches Korrelat in der FDG-PET/CT: Früher Prediktor für eine spätere Malignomentstehung? (2009) (0)
Häufigkeit von morphologischen Arteriosklerose-Manifestationen und 18F-FDG-Uptake in der Gefäßwand: eine PET/CT-Untersuchung (2009) (0)
Kombination von Chemoembolisation, Thermoablation und selektiver interstiteller Radiatio bei Patienten mit fortgeschrittenem hepatozellulärem Karzinom (2010) (0)
5.2 Befindlichkeitsstörungen und Lebensqualität bei Schilddrüsenfunktionsstörungen - insbesondere bei Hypothyreose und Schilddrüsenkarzinom (2004) (0)
5.5 Einfluss der Schilddrüsenstoffwechsellage auf den psychosomatischen Status bei Schilddrüsenkarzinom-Patienten (2004) (0)
Szintigraphie beim Schilddrüsenkarzinom (2004) (0)
Standardized uptake values (SUVs) in der onkologischen Ganzkörper-68Ga-DOTATOC-PET/CT: Was ist physiologisch? (2009) (0)
Kann die FDG-PET/CT die Indikation zur Sentinel-Lymphknotenbiopsie bei Patientinnen mit Mammakarzinom erweitern? (2009) (0)
38-Chlorid-Resorption bei Patienten mit einem Mainz-Pouch-I (1997) (0)
Darstellung von Metastasen eines Schilddrüsenkarzinoms mittels 111In-Pentetreotide-Szintigraphie (1995) (0)
Knochenmarkszintigraphie und Magnetresonanztomographie beim Plasmozytom (1989) (0)
Molekulare Bildgebung bei gastrointestinalen Stromatumoren: Rolle der Positronen-Emissions-Tomographie mit [18F]-2-Fluordeoxyglukose (2005) (0)
68Ga-DOTATOC-PET/CT-Bildgebung und Somatostatin-Rezeptor-“Fingerprints“ in physiologischen humanen Geweben: „SUVmax trifft mRNA-Expression“ (2010) (0)
Behandlung der Struma mit Euthyreose mit 200 (µg Jodid/die - Ergebnisse im Vergleich zu Levothyroxin (1992) (0)
Segmentale Radioembolisation mittels Yttrium 90 und ihre Auswirkungen auf Volumenveränderungen der Leber (2012) (0)
Selektive interne Radiotherapie mit Yttrium-90 Glasmikrosphären (TheraSphere) bei intrahepatisch fortgeschrittenem hepatozellulärem Karzinom (2009) (0)
Somatostatinrezeptor-PET / CT Stand : 3 / 2017 – AWMF-Registernummer : 031 – 046 (2017) (0)
Wertigkeit des PET/CT bei Kopf-Hals-Tumoren (2004) (0)
Diagnostischer Benefit der 131-I-SPECT/CT gegenüber der 131-I-Szintigraphie bei der Bildgebung von Patienten mit differenziertem Schilddrüsenkarzinom (2010) (0)
Die Galliumszintigraphie in der Osteomyelitisdiagnostik (2008) (0)
Ganzkörper-PET/CT bei Patienten mit malignen Lebertumoren - Einfluss auf die Therapieentscheidung bei geplanter RF-Ablation (2005) (0)
124I-PET(/CT) bei differenzierten Schilddrüsenkarzinomen (2009) (0)
Bedeutung der nuklearmedizinischen Bildgebung für die Lymphknotenchirurgie (2008) (0)
In-vivo Darstellung der Zellmigration von99mTC-HMPAO markierten transplantierten Leberstammzellen beim Kaninschen (2005) (0)
Vergleich des FDG-PET/MRT mit dem PET/CT für das lokale Tumorstaging des Mammakarzinoms (2014) (0)
Vergleich der diagnostischen Genauigkeit der FDG-PET/CT und der Sonographie bei der Detektion axillärer Lymphknotenmetastasen des Mammakarzinoms (2012) (0)
Radioembolisation hepatischer Tumore mit Yttrium-90: Perfusionsumverteilung nach Coilembolisation intrahepatischer Arterien (2012) (0)
Frühe und späte HMPAO-SPECT während eines epileptischen Anfalls (1990) (0)
Evaluation der 68Ga-DOTATOC PET/MRT im Vergleich zur 68Ga-DOTATOC PET/CT beim Ganzkörperstaging von Patienten mit neuroendokrinen Tumoren (2017) (0)
„...mehr als die Summe seiner Teile...“: Multimodales Tumorimaging: Kombinierte radiologische und nuklearmedizinische Diagnostik und Therapiesteuerung (2012) (0)
Automatische Läsionserkennung und Auswertung in der PET/CT: Evaluation am Beispiel des hepatisch metastasierten CRC (2011) (0)
Überleben und Response-Rate nach Radioembolisation mit Yttrium-90 Glas-Mikrosphären beim fortgeschrittenen hepatozellulärem Karzinom: Eine europäische Phase II Pilot-Studie (2009) (0)
PET/MRT – der nächste Quantensprung in der Diagnostik?: Kombinierte PET/MRT-Bildgebung am Universitätsklinikum EssenKombinierte PET/MRT-Bildgebung am Universitätsklinikum Essen (2013) (0)
Immunszintigraphie mit 131J-markierten monoklonalen anti-ß-HCG-Antikörpern in der Nachsorge von Hodentumoren (1990) (0)
PET und PET/CT im Therapiemonitoring von soliden Tumoren und Lymphomen (2006) (0)
Die Rolle der PET-CT beim Prostatakarzinom (2009) (0)
Fehlermöglichkeiten der intraoperativen antikörpergeleiteten Tumorlokalisation mit 131 J-markierten Antikörpern (1991) (0)
„One-stop-shop“ Staging: Ganzkörper FDG-PET/CT oder MRT zur Detektion ossärer Metastasen? (2010) (0)
PET/CT: Welche Rolle kommt dem Radiologen zu? (2010) (0)
Editorial: Radionuklidengpass - Ursachen und Lehren (2009) (0)
T-Staging des Prostatakarzinoms; Sonographie vs. MRI (1987) (0)
Kernspinresonanztomografie für Nuklearmediziner (2014) (0)
Radiofrequenzablation extrahepatischer Metastasen bei Patienten mit hepatozellulärem Karzinom (2009) (0)
Sicherheit und Effektivität einer selektiven internen Radiotherapie mit 90Yttrium-Microsphären (TheraSphere®) bei intrahepatisch fortgeschrittenem hepatozellulärem Karzinom (2007) (0)
Rektale und anale FDG-Aufnahme in der PET/CT: Was ist noch normal? (2008) (0)
Stellenwert der PET/CT beim Rezidiv des kolorektalen Karzinoms (2008) (0)
Polymorphismen des Gens für den Glukosetransporter (GLUT1) und ihr Einfluss auf die 18FDG-Aufnahme und Aggressivität des Mammakarzinoms (2010) (0)
Simultane PET/MRT mit 68Ga-DOTATOC bei Patienten mit neuroendokrinen Tumoren – Erste Resultate (2012) (0)
Hochkonzentriertes, jodhaltiges, intravenöses Kontrastmittel in der PET/CT: Sind kontrastmittelassoziierte PET-Artefakte zu erwarten? (2008) (0)
Malignes Phäochromozytom der Harnblase. Fallbericht und Literaturübersicht (1993) (0)
Nuklearmedizinische Diagnostik und Therapie in der Uroonkologie (2019) (0)
PET/CT als Responseprediktor bei ösophagealen und gastrointestinalen Karzinomen (2009) (0)
Diagnostische Genauigkeit der FDG-PET/CT bei Kopf-Hals Tumoren (2007) (0)
In-vivo Darstellung der Zellmigration von 99mTC-HMPAO markierten transplantierten Leberstammzellen beim Kaninschen (1993) (0)
Genauigkeit der PET/CT-Kolonographie bei der Beurteilung kolorektaler Tumore (2006) (0)
Immunszintigraphie unter Verwendung von CA-125-Antikörpern bei der Behandlung des Ovarialkarzinoms (1990) (0)
Speicheldrüsenschädigung bei Radioiodtherapie – Dosimetrieergebnisse und deren Implikationen (2010) (0)
Radioembolisation hepatischer Tumore mit Yttrium-90: brauchen wir SPECT/CT um extrahepatische Shunts zu identifizieren? (2012) (0)
18F-FDG- PET/MRT der Brust: Vergleich 16 versus 4 Kanal Spule im Rahmen des lokalen Stagings bei Mammakarzinom Patientinnen: erste Ergebnisse (2014) (0)
Stellenwert der ablativen Tumortherapie beim HCC: „eine reale Brücke“ zur Lebertransplantation? (2013) (0)
Multimodale Dünndarmdiagnostik mittels PET/MR Enterografie: Erste Erfahrungen (2015) (0)
Tumormarker für Schilddrüsenkarzinome (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andreas Bockisch?

Andreas Bockisch is affiliated with the following schools:

University of Duisburg-Essen

Andreas Bockisch's Academic­Influence.com Rankings